ESPR
Esperion Therapeutics, Inc.
$3.16
+0.01 (+0.32%)
At close · Jul 7
Market Cap
$821.21M
Shares
257,431,942
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.16
Open$3.15
Day$3.15–3.17
52W$1.10–4.18
Avg vol 30d9.4M
Short int20.7M · 8.0% float · 1.8d
Short vol33%
Last earningsJan 12, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 8
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+4%
above
Price vs 50-day avg
+5%
above
RSI (14)
63
neutral
MACD trend
Negative
52-week position
67%
mid-range
Momentum
relative strength
1-month return
+1%
trailing
6-month return
−11%
trailing
YTD return
−15%
this year
Relative strength
−19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
7 of 206 funds reported for Jun 30 · net +97.0K sh shares · +1 new
Insider flow
Distributing
Net -$240.4K over 90 days · 100% sells
Short interest
Rising
8.05% of float · ▲ +10.7% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
206 holders — near 3-yr high, broad support
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
+21%
Y/Y
EPS growth
+61%
Y/Y
Free cash flow
$-13.1M
Balance sheet
$167.9M
net cash
Quant / Vol
risk profile
Volatility
90%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
0.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+4%
Bullish
Price vs 50-day avg
+5%
Bullish
RSI (14)
63
Neutral
MACD trend
Negative
Bearish
52-week position
67%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
7 of 206 funds reported for Jun 30 · net +97.0K sh shares · +1 new
Insider flow
Distributing
Net -$240.4K over 90 days · 100% sells
Short interest
Rising
8.05% of float · ▲ +10.7% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
206 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $3 · 67%
52-wk high $4
vs 200-day avg +4%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Q4 retail prescription equivalents sequential Q/Q growth | 11.3% | Q4 2025 | — |
| Q4 retail prescription equivalents Y/Y growth | 34% | Q4 2025 | — |
| Royalty revenue | $14.6M | Q4 2025 | — |
| Unique healthcare providers prescribing NEXLETOL and NEXLIZET | 44,991 | FY2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ESPR
this stock
Esperion Therapeutics, Inc.
|
$821.21M | -14.6% | +21.3% | — | 8.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$53.49B | +7.4% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$51.08B | +5.2% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$42.94B | -3.6% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ESPR | +0.3% | +1.0% | -11.0% | +0.0% | -14.6% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -0.6% | -0.4% | -18.6% | -0.1% | -24.2% |